PROCEPT BioRobotics Announces New CPT Category I Code From The AMA For Aquablation Therapy To Treat Benign Prostatic Hyperplasia
Portfolio Pulse from Benzinga Newsdesk
PROCEPT BioRobotics (NASDAQ:PRCT) announced that the AMA has established a new CPT Category I code for its Aquablation therapy to treat benign prostatic hyperplasia, effective January 1, 2026. This change reflects increased utilization and strong clinical outcomes.
June 17, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics has received a new CPT Category I code from the AMA for its Aquablation therapy, effective January 1, 2026. This reflects increased utilization and strong clinical outcomes, potentially boosting the company's market position.
The new CPT Category I code signifies recognition of the therapy's effectiveness and increased usage, which could lead to higher adoption rates and revenue growth for PROCEPT BioRobotics. This is a positive development for the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100